Work

Clinical and Virologic Response to Episodic Acyclovir for Genital Ulcers Among HIV-1 Seronegative, Herpes Simplex Virus Type 2 Seropositive African Women: A Randomized, Placebo-Controlled Trial

Year: 2011

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Abstract: In Brief In a randomized trial among African women with recurrent genital herpes, episodic acyclovir therapy resulted in modestly greater likelihood of lesion healing (hazard ratio [HR] = 1.48, P = 0.098; mean, 5.1 vs. 6.0 days) and cessation of herpes simplex virus shedding (HR = 1.88, P = 0.008; mean, 3.0 vs. 5.0 days) compared with placebo, similar to results of studies in high-income countries (ClinicalTrials.gov registration NCT00808405). A standard 5-day oral acyclovir course shortened time to lesion healing and to cessation of HSV shedding among African women with recurrent genital herpes, similar to results of studies in high-income countries.

Source: Sexually Transmitted Diseases

DOI: 10.1097/olq.0b013e31823b50c6